| Literature DB >> 16205738 |
Gerd Fätkenheuer1, Anton L Pozniak, Margaret A Johnson, Andreas Plettenberg, Schlomo Staszewski, Andy I M Hoepelman, Michael S Saag, Frank D Goebel, Jürgen K Rockstroh, Bruce J Dezube, Tim M Jenkins, Christine Medhurst, John F Sullivan, Caroline Ridgway, Samantha Abel, Ian T James, Mike Youle, Elna van der Ryst.
Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16205738 DOI： 10.1038/nm1319
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440